Showing 3801-3810 of 5773 results for "".
- Recent Alimera Data Featured in Scientific Programming at ARVOhttps://modernod.com/news/recent-alimera-data-featured-in-scientific-programming-at-arvo/2480813/Alimera Sciences announced today that Iluvien will be highlighted in various scientific abstracts at the annual Association for Research in Vision and Ophthalmology (ARVO) conference being held in Denver, Colorado from May 1-4 and virtually May 11-12, 2022.
- Ocuphire Completes Last Clinical Trial Supporting the Planned 2022 NDA Submission of Nyxol for Reversal of Mydriasishttps://modernod.com/news/ocuphire-completes-last-clinical-trial-supporting-the-planned-2022-nda-submission-of-nyxol-for-reversal-of-mydriasis/2480812/Ocuphire Pharma announced positive results in the MIRA-4 pediatric safety trial investigating its product candidate Nyxol for the reversal of pharmacologically-induced mydriasis (dilation of pupil). The results demonstrated that Nyxol’s efficacy and safety in pediatric subjects 3-11 ye
- Oyster Point Pharma to Present New Analyses at ARVO 2022https://modernod.com/news/oyster-point-pharma-to-present-new-analyses-at-arvo-2022/2480807/Oyster Point Pharma announced the presentation of data analyses at the Association for Research in Vision and Ophthalmology (ARVO) 2022, being held on May 1-4. “We are pleased to be presenting new analyses of the pivotal trial data of Tyrvaya&n
- Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational NOV03 at ASCRShttps://modernod.com/news/bausch-lomb-presents-data-from-first-pivotal-phase-3-trial-of-investigational-nov03-at-ascrs/2480800/Bausch + Lomb and Novaliq announced that data from the first pivotal phase 3 trial (GOBI) of NOV03 (perfluorohexyloctane), which is being investigated as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with Meibom
- Théa Introduces iVIZIA OTC Eye Care Products in UShttps://modernod.com/news/thea-introduces-ivizia-otc-eye-care-products-in-us/2480796/Théa Pharma announced the availability of the iVIZIA line of over-the-counter (OTC) eye care products in the United States. The iVIZIA OTC product line includes lubricating eye drops, lubricating eye gel, and three options for daily hygiene of sensitive eyelids. iVIZIA
- Johnson & Johnson Vision Introduces Next-Generation TearScience Activator Clear for Treatment of MGDhttps://modernod.com/news/johnson-johnson-vision-introduces-next-generation-tearscience-activator-clear-for-treatment-of-mgd/2480795/Johnson & Johnson Vision announced the availability of the next-generation TearScience Activator Clear. Building on the legacy of the TearScience LipiFlow Thermal Pulsation System—a fully automated treatment for meibomian gland dysfunction (MGD)—Johnson & Johnson Vis
- Haag-Streit Launches the Eyestar 900 Anterior Chamber Suitehttps://modernod.com/news/haag-streit-launches-the-eyestar-900-anterior-chamber-suite/2480794/Haag-Streit has announced the launch of the Eyestar 900 Anterior Chamber Suite (AC-Suite) to compliment the Cataract Suite. The AC-Suite is designed to meet the growing demand for improved outcomes in cataract and refractive surgery. The Eyestar 900 is based on swep
- CorneaGen Releases New DSEK Surgery Device to Help Streamline DSEK Surgerieshttps://modernod.com/news/corneagen-advances-next-generation-of-dsek-surgery-innovation/2480789/CorneaGen announced the release of the EndoSerter-PL, a new FDA approved, single-use graft insertion device preloaded with processed tissue to help streamline DSEK surgeries. “We’re incredibly excited to deliver the EndoSerter-PL, our latest innovation in
- Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 ASCRShttps://modernod.com/news/glaukos-technologies-featured-in-numerous-scientific-abstracts-at-the-2022-ascrs/2480788/Glaukos announced that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April 22–26, 2022 in Washington, DC. In addition, Glaukos is sponsoring an educational symposium
- J&J Vision Presents Data Validating Improved Surgical Outcomes and Surgeon Satisfaction at ASCRShttps://modernod.com/news/johnson-johnson-vision-presents-data-validating-improved-surgical-outcomes-and-surgeon-satisfaction-across-cataract-and-refractive-portfolio-at-ascrs/2480787/Johnson & Johnson Vision will present and/or support 46 company-sponsored and investigator-led studies evaluating innovations and outcomes across its surgical portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Washington, DC, April 22-26.